We are proud to share our latest review article on #PC111, a fully human anti-Fas Ligand monoclonal antibody, and its potential as a disease-modifying therapy for #pemphigus and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (#SJSTEN).
This work highlights how PC111 can block blister formation and keratinocyte apoptosis without the need for systemic immunosuppression—offering a novel, targeted approach for these severe dermatological conditions.
Read the full article in the Journal of Dermatological Treatment:
“Treatment of pemphigus and other neglected skin conditions with PC111, a human anti-Fas Ligand monoclonal antibody: a potential disease modifier“
or download in PDF format.
Huge thanks to our co-authors and collaborators for their dedication and insight. Let’s keep pushing the boundaries of dermatological innovation!